• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[严重肺栓塞纤溶过程中的血流动力学变化]

[Hemodynamic course during fibrinolysis in severe pulmonary embolism].

作者信息

Ohayon J, Colle J P, Tauzin-Fin P, Lorient-Roudaut M F, Besse P

出版信息

Arch Mal Coeur Vaiss. 1986 Apr;79(4):445-53.

PMID:3090962
Abstract

Seventy seven cases of severe pulmonary embolism (Miller index greater than 13 points) including 61 acute (under 5 days) and 16 subacute episodes, underwent continuous haemodynamic monitoring during treatment with either urokinase 2 000 U/kg/h for 24 hours with heparin (Group I: 18 patients), or urokinase 4 500 U/kg/h for 12 hours without heparin (Group II: 47 patients), or with streptokinase 2 00 000 U over 10 hours (Group III: 12 patients). Efficacy was defined as greater than 20% improvement of Miller index at control angiography after 48 hours (Group I: 10 patients, Group II: 31 patients, Group III: 8 patients). In the 49 patients (63%) with good results, the Miller index fell by about 50% with a significant increase in cardiac index (20%) from the 12th hour. There was a concomitant fall in pulmonary systolic arterial pressure (35%). In the 28 patients (37%) with partial improvement a 20% increase in cardiac index and an 18% fall in pulmonary systolic arterial pressure were observed only in the high dose urokinase group, despite incomplete pulmonary revascularisation demonstrating the vasodilator effect of this protocol. Fibrinolysis was repeated in the patients with incomplete results or a Miller index of over 13 points, leading to improvement in 78% of patients. Accelerated lysis of pulmonary embolism leads to rapid normalisation of haemodynamic parameters and improves the prognosis of massive pulmonary embolism by reducing the number of recurrences and the mortality rate (4%).

摘要

77例严重肺栓塞患者(米勒指数大于13分),其中包括61例急性发作(病程小于5天)和16例亚急性发作,在接受治疗期间进行了连续血流动力学监测。治疗方案如下:第一组18例患者,使用尿激酶2000 U/kg/h,持续24小时,并联合肝素治疗;第二组47例患者,使用尿激酶4500 U/kg/h,持续12小时,不联合肝素治疗;第三组12例患者,使用链激酶200000 U,持续10小时。疗效定义为48小时后对照血管造影时米勒指数改善超过20%(第一组10例患者,第二组31例患者,第三组8例患者)。在49例(63%)治疗效果良好的患者中,从第12小时起,米勒指数下降约50%,心指数显著升高(20%),同时肺收缩压下降(35%)。在28例(37%)部分改善的患者中,尽管肺血管再通不完全,但仅在高剂量尿激酶组观察到心指数升高20%,肺收缩压下降18%,这表明该方案具有血管舒张作用。对治疗效果不完全或米勒指数超过13分的患者重复进行溶栓治疗,78%的患者病情得到改善。加速溶解肺栓塞可使血流动力学参数迅速恢复正常,并通过减少复发次数和死亡率(4%)改善大面积肺栓塞的预后。

相似文献

1
[Hemodynamic course during fibrinolysis in severe pulmonary embolism].[严重肺栓塞纤溶过程中的血流动力学变化]
Arch Mal Coeur Vaiss. 1986 Apr;79(4):445-53.
2
[Local thrombolysis with urokinase in acute massive pulmonary embolism].急性大面积肺栓塞的尿激酶局部溶栓治疗
Dtsch Med Wochenschr. 1984 Jan 13;109(2):55-8. doi: 10.1055/s-2008-1069138.
3
The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study.尿激酶-链激酶治疗肺栓塞的II期试验:一项全国性合作研究。
Thromb Diath Haemorrh. 1975 Jun 30;33(3):464-76.
4
Rapid haemodynamic improvement following saruplase in recent massive pulmonary embolism.近期大面积肺栓塞患者使用沙芦普酶后血流动力学迅速改善。
Thromb Haemost. 1998 Feb;79(2):264-7.
5
[Fibrinolysis therapy in massive lung embolism. Experiences in 10 patients 1982-1984].[大面积肺栓塞的纤溶治疗。1982 - 1984年10例患者的经验]
Schweiz Med Wochenschr. 1985 Aug 6;115(31-32):1074-9.
6
Local fibrinolytic therapy in acute pulmonary embolism.急性肺栓塞的局部纤维蛋白溶解疗法。
Ann Radiol (Paris). 1987;30(2):151-5.
7
The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. The UKEP Study Research Group.UKEP研究:关于两种局部尿激酶方案治疗大面积肺栓塞的多中心临床试验。UKEP研究组
Eur Heart J. 1987 Jan;8(1):2-10.
8
Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up.链激酶与阿替普酶两小时治疗方案对急性大面积肺栓塞的疗效比较:即时临床和血流动力学结果及一年随访
J Am Coll Cardiol. 1998 Apr;31(5):1057-63. doi: 10.1016/s0735-1097(98)00068-0.
9
[Multicenter study of 2 urokinase protocols in severe pulmonary embolism. Research Group on Urokinase and Pulmonary Embolism].[两种尿激酶方案治疗严重肺栓塞的多中心研究。尿激酶与肺栓塞研究组]
Arch Mal Coeur Vaiss. 1984 Jul;77(7):773-81.
10
[Effects of thrombolytic agents on pulmonary and venous clots in severe pulmonary embolism (author's transl)].
Nouv Presse Med. 1981 Apr 4;10(15):1189-92.

引用本文的文献

1
Thrombolytic therapy for pulmonary embolism.肺栓塞的溶栓治疗。
Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD004437. doi: 10.1002/14651858.CD004437.pub6.
2
Thrombolytic therapy for pulmonary embolism.肺栓塞的溶栓治疗
Cochrane Database Syst Rev. 2018 Dec 18;12(12):CD004437. doi: 10.1002/14651858.CD004437.pub5.
3
Indications for thrombolytic therapy in acute pulmonary embolism.急性肺栓塞溶栓治疗的适应证
Tex Heart Inst J. 1989;16(1):19-26.
4
Comparative tolerability profiles of thrombolytic agents. A review.溶栓药物的耐受性比较概况。综述。
Drug Saf. 1993 Jan;8(1):19-29. doi: 10.2165/00002018-199308010-00004.